Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

• Status: Terminated
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with gastroesophageal reflux disease (GERD) are either treated for 4 weeks with a standard dose (20mg) of omeprazole, a drug of first choice, or by an individualized dosing (20 or 60mg/day) according how fast the patient can metabolize (eliminate) the drug. The individual elimination capacity is genetically controlled and therefore all patients will be genotyped prior to therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Matthias Schwab
• Treatments: Omeprazole

Criteria

Inclusion Criteria:

• Patients with GERD grade A and B (mild to moderate severe disease) diagnosed by routine endoscopy will be recruited in different clinical and ambulant centres of gastroenterology; written informed consent is obligatory

• Range of Age: 20-70

• BMI: 20-30

Exclusion Criteria:

• Patients who are allergic to proton-pump inhibitors or show incompatibility

• Patients who have lactase deficiency

• Patients who have severe chronic disease

• Patients who participated in another study during the last three months

• Patients who are pregnant